Dolutegravir/Lamivudine and Sucralfate Interaction

Drug interaction information between Dolutegravir/Lamivudine and Sucralfate.

Dolutegravir/Lamivudine and Sucralfate have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Dolutegravir/Lamivudine and Sucralfate. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Dolutegravir/Lamivudine

Integrase Inhibitor / NRTI Combination

Drug B

Sucralfate

Mucosal Protective Agent

How They Interact

Sucralfate contains minerals that can bind to dolutegravir in your stomach, preventing the medicine from being absorbed into your bloodstream.

FDA Label Information

Medications containing polyvalent cations (e.g., Mg or Al): Cation-containing antacids a or laxatives Sucralfate Buffered medications ↓Dolutegravir Administer DOVATO 2 hours before or 6 hours after taking medications containing polyvalent cations.

Dolutegravir/Lamivudine Also Interacts With

View all Dolutegravir/Lamivudine interactions →

Frequently Asked Questions

What SPL severity band is on file for Dolutegravir/Lamivudine + Sucralfate?

Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Sucralfate has 20 labeled pairs on file vs Dolutegravir/Lamivudine's 9. In the minor band specifically: Dolutegravir/Lamivudine has 4 (also Carbamazepine, Rifampin, Dolutegravir); Sucralfate has 18 (also Warfarin, Ketoconazole, Ciprofloxacin, Ofloxacin).

What mechanism field is on file for Dolutegravir/Lamivudine and Sucralfate?

Sucralfate contains minerals that can bind to dolutegravir in your stomach, preventing the medicine from being absorbed into your bloodstream.

Sucralfate's labeled portfolio outnumbers Dolutegravir/Lamivudine

SPL source-record counts only. This page's band is minor · classes on file: Dolutegravir/Lamivudine (Integrase Inhibitor / NRTI Combination); Sucralfate (Mucosal Protective Agent).

Dolutegravir/Lamivudine

1 major · 4 moderate · 4 minor · 9 total

Sucralfate

1 major · 1 moderate · 18 minor · 20 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.